

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0580 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	Immediately tell the resident, the resident's doctor, and a family member of situations (injury/decline/room, etc.) that affect the resident. 37342 Based on records reviewed and interviews, for 13 of 22 sampled residents (Resident #1, #3, #5, #6, #9, #10, #11, #14, #15, #16, #17, #18, and #22) the Facility failed to ensure nursing staff notified their Attending Physicians when on 06/24/24, during the 07:00 A.M. to 03:00 P.M. shift, the administration of multiple medications to each of these residents, were omitted by nursing. Findings include: The Facility Policy, titled Change of Condition in a Resident Status, dated 03/2017, indicated the Facility would notify the resident's Attending Physician of any changes in the resident's medical condition including accidents or incidents involving the resident. The Facility Policy, titled Oral Medication Administration, dated as revised 04/2022, indicated nursing staff would administer medications as ordered, and would notify the practitioner and document accordingly in the event that a resident refused medications. The Facility Policy, titled Accidents, dated as revised 04/2022, indicated all accidents and incidents would be investigated, including medication errors, and the attending physician would be notified. Review of the Medication Administration Records (MAR) for the following residents indicated the following medications were omitted during the 7:00 A.M. to 3:00 P.M., shift on 06/24/24: Resident #1: -Metoprolol Succinate (antihypertensive) 25 mg Extended Release tablet. -Paroxetine (mood stabilizer) 20 mg tablet -Xarelto (blood thinner) 20 mg tablet. Resident #3: -Amiodarone (antihypertensive) 200 mg tablet (continued on next page)		

Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE	TITLE	(X6) DATE
FORM CMS-2567 (02/99) Previous Versions Obsolete	Event ID: 225545	Facility ID: 225545 If continuation sheet Page 1 of 10

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0580 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	-Aspirin (antiplatelet) Chewable tablet by mouth. -Folic Acid (for renal disease) 1 mg tablet -Lidocaine (for pain) patch 5% apply to bilateral shoulders one time daily in the morning -Midodrine (treats low blood pressure) 10 mg tablets administer two tablets (20 mg) Mondays Wednesdays and Fridays. -Pantoprazole Sodium (for renal disease) 40 mg packet. -Renal-Vite (supplement) 0.8 mg tablet -Venlafaxine Hydrochloride (antidepressant) 150 mg tablet. -Cholecalciferol (vitamin D supplement) 400 unit tablet -Advair (for congestion) Diskus 250-50 micrograms (mcg) inhale two puffs. -Fludrocortisone Acetate (treats low blood pressure) 0.1 mg tablet. -Sevelamir Hydrochloride (lowers phosphorous) 800 mg tablet by mouth with every meal. Resident #5: -Divaloprex Sodium (antiseizure) Extended Release 500 mg tablet, administer two tablets (1000 mg) by mouth every morning. -Empagliflozin (treats diabetes) 10 mg tablet. -Finasteride (treats enlarged prostate) 5 mg. -Flomax (treats enlarged prostate) 0.4 mg. -Metoprolol Succinate Extended Release 50 mg tablet. -Apixaban (anticoagulant) 2.5 mg tablet. Resident #6: -Escitalopram Oxalate (antidepressant) 20 mg tablet. -Aspirin Chewable 81 mg tablet. -Fluoxetine Hydrochloride (antidepressant) 20 mg tablet. -Lidocaine Patch 4% apply to affected area every morning and remove every night. (continued on next page)		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0580 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	-Losartan Potassium (antihypertensive) 50 mg tablet. -Midodrine Hydrochloride 5 mg tablet, Monday, Wednesday, and Friday. -Advair Diskus 500/50 mcg per activation one puff inhale orally every 12 hours. Resident #9: -Ipratropium-Albuterol (bronchodilator) Solution 0.5-2.5 mg per milliliter (ml) inhalation. Resident #10: -Humalog (insulin) 100 units per ml, inject 18 units subcutaneously (under the skin) with breakfast. -Humalog 100 units per ml, inject 18 units subcutaneously with lunch. -Humulin N (insulin) 100 units per ml, inject 30 units subcutaneously every morning with breakfast. -Advair Inhalation Aerosol 230-21 mcg per activation two puffs inhale orally two times every day. -Midodrine Hydrochloride 5 mg tablet, (missed 1:00 P.M. dose). Resident #11: -Cetirizine (anticholinergic) 10 mg tablet. -Famotidine (antacid) 20 mg tablet. -Omeprazole (protein pump inhibitor) 20 mg capsule. -Torsemide (diuretic) 20 mg tablet. Resident #14: -Lidocaine Patch 4% apply to affected area every morning and remove every night. -Tresiba FlexTouch (insulin) 200 units per ml inject 24 units subcutaneously. -Fingerstick Blood Glucose measurement three times daily before meals (11:30 A.M. scheduled measurement was not done). -Lispro (insulin) 100 units per ml solution inject 7 units, daily before each meal (08:00 A.M., and 11:30 A.M. doses were not administered). -Albuterol Sulfate Hydrofluoroalkane (treats bronchospasm) Inhalation Aerosol Solution 108 (90 base) micrograms (mcg) per activation two puffs (12:00 P.M. dose was not administered). (continued on next page)		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0580 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	Resident #15: -Buspirone Hydrochloride (anxiolytic) 7.5 mg tablet (1:00 P.M. dose was not administered). -Gabapentin (for nerve pain) 300 mg tablet (1:00 P.M., dose was not administered). -Ipratropium-Albuterol Solution 0.5-2.5 mg per ml inhale (11:00 A.M., dose was not administered). Resident #16: -Lidocaine Patch 5% apply to affected area every morning and remove every night. -Renal-Vite 1 mg tablet. -Hyralazine Hydrochloride (antihypertensive) 50 mg tablet. -Novolog (insulin) 100 units per ml inject 2 units subcutaneously three times a day with meals. -Pancrelipase (replaces pancreatic enzymes) 24,000-76,000 unit delayed release capsules administer 2 capsules with meals (12:00 P.M., dose was not administered). -Renvela (lowers blood phosphorous) 800 mg tablets with meals (breakfast and lunch not administered). Resident #17: -Amlodipine (antihypertensive) 5 mg tablet administer 2 tablets. -Lidocaine Patch 5% apply two patches to affected area every morning and remove every night. -Renal-Vite 0.8 mg tablet. -Heparin Sodium (anticoagulant) 5,000 units per ml, inject 1 ml subcutaneously twice a day. -Sevelamer Carbonate (lowers phosphorous) 800 mg tablet with meals (breakfast and lunch not administered). Resident #18: -Glargine (insulin) 300 units per ml, inject 28 units subcutaneously. -Lidoderm Patch 5% apply to left knee topically in the morning and remove at night. -Lokelma (lowers blood potassium level) 5 gram Oral Packet administer 3 packets. -Metoprolol Succinate Extended Release 200 mg tablet. -Procardia XL (antihypertensive) Extended Release 30 mg tablet administer two tablets. (continued on next page)		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0580 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	-Torsemide 20 mg tablet administer three tablets. -Enalapril Maleate (antihypertensive) 10 mg tablet. -Terazosin Hydrochloride (antihypertensive) 1 mg tablet administer three tablets. Resident #22: -Amlodipine 10 mg tablet. -Aspirin Enteric Coated 81 mg tablet. -Atorvastatin Calcium 80 mg tablet. -Hydralazine Hydrochloride 10 mg. -Sertraline (mood stabilizer) 25 mg tablet. -Carvedilol (antihypertensive) 25 mg tablet. -Ticagrelor (platelet aggregator inhibitor) 90 mg. -Sevelamir Hydrochloride 800 mg tablet by mouth with meals (breakfast and lunch not administered). Further review of the Medical Records indicated there was no documentation to support that these residents' Attending Physicians were notified of the omission of these medications. During an interview on 07/09/24 at 11:48 A.M., Unit Manager #1 said that on 06/24/24 at 09:15 A.M., she was asked by the Administrator to float to the Beechwood Unit to administer medications. Unit Manager #1 said she was the only nurse on the unit and said she was unable to administer all of the medications on the unit. Unit Manager #1 said she did not notify any of the residents' physicians whose medications were omitted. During an interview on 07/07/24 at 12:16 P.M., Unit Manager #2 said she was not in the Facility on 06/24/24, and on 06/25/24 she was made aware that there missed medication for many of the residents on the Beechwood Unit. Unit Manager #2 said she did not report the missed medications to the residents' physicians, and did not ask anyone if the omitted medication were reported to the physicians. During an interview on 07/09/24 at 03:01 P.M., the Regional Nurse said nursing staff were expected to report omitted medication doses to the physician in accordance with Federal regulations and Facility Policy.		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0760 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	Ensure that residents are free from significant medication errors. 37342 Based on records reviewed and interviews, for 13 of 22 sampled residents (Resident #1, #3, #5, #6, #9, #10, #11, #14, #15, #16, #17, #18, and #22), the Facility failed to ensure the residents were free from significant medication errors, when on 06/24/24, nursing omitted and did not administer several medications these residents, including critical medications such as insulin doses, anti-hypertensive's, and anticoagulants, placing then at risk for an adverse reaction related to the missed doses of the medications. Findings include: The Facility Policy, titled Medication Monitoring and Management, dated 11/2021, indicated medications would be administered at the frequency and times indicated in the prescriber orders, and medication administrations would be documented. The Facility Policy, titled Oral Medication Administration, dated as revised 04/2022, indicated nursing staff would administer medications as ordered. Review of the Medication Administration Records (MAR) for the following residents indicated the following medication doses were omitted during the 7:00 A.M., to 3:00 P.M., shift on 06/24/24: Resident #1: -Metoprolol Succinate (antihypertensive) 25 mg tablet. -Paroxetine (mood stabilizer) 20 mg tablet. -Xarelto (blood thinner) 20 mg tablet. Resident #3: -Amiodarone (antihypertensive) 200 mg tablet. -Aspirin (antiplatelet) Chewable tablet. -Folic Acid (for renal disease) 1 mg tablet. -Lidocaine (for pain) patch 5% to bilateral shoulders one time daily in the morning. -Midodrine (treats low blood pressure) 10 mg tablets administer two tablets (20 mg). -Pantoprazole Sodium (for renal disease) 40 mg packet. -Renal-Vite (supplement) 0.8 mg tablet. -Venlafaxine Hydrochloride (antidepressant) 150 mg tablet. (continued on next page)		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0760 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	-Cholecalciferol (vitamin D supplement) 400 unit tablet. -Advair (for congestion) Diskus 250-50 micrograms (mcg) inhale two puffs. -Fludrocortisone Acetate (treats low blood pressure) 0.1 mg tablet. -Sevelamir Hydrochloride (lowers phosphorous) 800 mg tablet. Resident #5: -Divaloprex Sodium (antiseizure) Extended Release 500 mg tablet, two tablets (1000 mg). -Empagliflozin (treats diabetes) 10 mg tablet. -Finasteride (treats enlarged prostate) 5 mg tablet. -Flomax (treats enlarged prostate) 0.4 mg capsule. -Metoprolol Succinate Extended Release 50 mg tablet. -Apixaban (anticoagulant) 2.5 mg tablet. Resident #6: -Escitalopram Oxalate (antidepressant) 20 mg tablet. -Aspirin Chewable 81 mg tablet. -Fluoxetine Hydrochloride (antidepressant) 20 mg tablet. -Lidocaine Patch 4% to affected area every morning. -Losartan Potassium (antihypertensive) 50 mg tablet. -Midodrine Hydrochloride 5 mg tablet. -Advair Diskus 500/50 mcg per activation one puff. Resident #9: -Ipratropium-Albuterol (bronchodilator) Solution 0.5-2.5 mg per milliliter (ml) inhalation. Resident #10: -Humalog (insulin) 100 units per ml, 18 units subcutaneously (under the skin). -Humalog 100 units per ml, 18 units subcutaneously. (continued on next page)		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0760 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	-Humulin N (insulin) 100 units per ml, 30 units subcutaneously. -Advair Inhalation Aerosol 230-21 mcg per activation two puffs. -Midodrine Hydrochloride 5 mg tablet, three tablets (15 mg) (1:00 P.M. dose not administered). Resident #11: -Cetirizine (anticholinergic) 10 mg tablet. -Famotidine (antacid) 20 mg tablet. -Omeprazole (protein pump inhibitor) 20 mg capsule. -Torsemide (diuretic) 20 mg tablet. Resident #14: -Lidocaine Patch 4% to affected area every morning. -Tresiba FlexTouch (insulin) 200 units per ml inject 24 units subcutaneously. -Fingerstick Blood Glucose measurement three times daily before meals (11:30 A.M. scheduled measurement was not done). -Lispro (insulin) 100 units per ml solution inject 7 units subcutaneously three times daily before each meal (08:00 A.M., and 11:30 A.M. doses were not administered) -Albuterol Sulfate Hydrofluoroalkane (treats bronchospasm) Inhalation Aerosol Solution 108 (90 base) micrograms (mcg) per activation two puffs inhale orally four times a day (12:00 P.M. dose was not administered). Resident #15: -Buspirone Hydrochloride (anxiolytic) 7.5 mg tablet (01:00 P.M. dose was not administered). -Gabapentin (for nerve pain) 300 mg tablet, two tablets (600 mg) three times daily (01:00 P.M., dose was not administered). -Ipratropium-Albuterol Solution 0.5-2.5 mg per ml every six hours (11:00 A.M., dose was not administered). Resident #16: -Lidocaine Patch 5% apply to affected area every morning. -Renal-Vite 1 mg tablet. (continued on next page)		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0760 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	-Hyralazine Hydrochloride (antihypertensive) 50 mg tablet. -Novolog (insulin) 100 units per ml inject 2 units subcutaneously. -Pancrelipase (replaces pancreatic enzymes) 24,000-76,000 unit delayed release capsules 2 capsules (12:00 P.M., dose was not administered). -Renvela (lowers blood phosphorous) 800 mg tablet. Resident #17: -Amlodipine (antihypertensive) 5 mg tablet, 2 tablets (10 mg). -Lidocaine Patch 5% two patches to affected area. -Renal-Vite 0.8 mg tablet. -Heparin Sodium (anticoagulant) 5,000 units per ml, inject 1 ml. -Sevelamer Carbonate (lowers phosphorous) 800 mg tablet. Resident #18: -Glargine (insulin) 300 units per ml, 28 units subcutaneously. -Lidoderm Patch 5% apply to left knee. -Lokelma (lowers blood potassium level) 5 gram Oral Packet administer 3 packets (15 grams). -Metoprolol Succinate Extended Release 200 mg tablet. -Procardia XL (antihypertensive) Extended Release 30 mg tablet, 2 tablets (60 mg). -Torsemide 20 mg tablet administer 3 tablets (60 mg). -Enalapril Maleate (antihypertensive) 10 mg tablet. -Terazosin Hydrochloride (antihypertensive) 1 mg tablet administer 3 tablets (3 mg). Resident #22: -Amlodipine 10 mg tablet. -Aspirin Enteric Coated 81 mg tablet. -Atorvastatin Calcium 80 mg tablet. -Hydralazine Hydrochloride 10 mg tablet. (continued on next page)		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 225545	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 07/09/2024
NAME OF PROVIDER OR SUPPLIER Regalcare at Courtyard-Medford		STREET ADDRESS, CITY, STATE, ZIP CODE 200 Governors Avenue Medford, MA 02155	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0760 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some	-Sertraline (mood stabilizer) 25 mg tablet. -Carvedilol (antihypertensive) 25 mg tablet. -Ticagrelor (platelet aggregator inhibitor) 90 mg tablet. -Sevelamir Hydrochloride 800 mg tablet. Further review of the Medical Records indicated there was no documentation to support that these residents' Attending Physicians were notified of the omission of these medication doses, and that nursing obtained new orders related to any of the missed medications. During an interview on 07/09/24 at 11:48 A.M., Unit Manager #1 said that on 06/24/24 at 09:15 A.M., she was asked by the Administrator to float to the Beechwood Unit to administer medications. Unit Manager #1 said she was the only nurse on the unit and said she was unable to administer all of the medications on the unit. Unit Manager #1 said omitted medication doses put residents at risk for potential negative outcomes such as high blood glucose levels, hypertension, and blood clots. During an interview on 07/07/24 at 12:16 P.M., Unit Manager #2 said she was not in the Facility on 06/24/24, and on 06/25/24 she was made aware that there missed medication doses for many of the residents on the Beechwood Unit, and said omitted medication doses put residents at risk for negative effects such as high blood glucose levels and hypertension. During an interview on 07/09/24 at 03:01 P.M., the Regional Nurse said nursing staff were expected to report omitted medication doses to the physician in accordance with Federal regulations and Facility Policy.		